Clinical Investigation of the Cardioprotective Effect of Early Administration of SGLT2 in Patients Presented With AMI

Sponsor
Mohammad Hussien Tantawy Soliman
Study ID
NCT06009874
Status
Recruiting
Apply to this trial

Conditions

  • Myocardial Infarction

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Dapagliflozin 10mg Tab — DRUG
    patients will be treated with DAPA 10 mg once daily for three months
  • Placebo — DRUG
    patients will be treated with a placebo tab once daily for three months

Study Details

This study aims to investigate the effect of early administration of DAPA during ischemia and before pPCI on infarct size, reperfusion injury-related myocardial damage, cardioprotection from HF, and renoprotection from AKI in patients with AMI.

Key Dates

Start date
Oct 31, 2023
Status verified
Aug 2023
Primary completion
Aug 31, 2026
Completion
Aug 31, 2026

Study Design

Enrollment
80 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION

Arms

  • Active Comparator: Dapagliflozin group
    patients with MI will be treated with DAPA 10 mg once daily for three months.
  • Placebo Comparator: Placebo group
    patients with MI will be treated with a matching placebo once daily for three months.

Primary Outcome Measure

difference in infarct size [ Time Frame: 3 months ]

Central Contacts

Related Studies